Evaluation of Vitamin E as An Add on with Standard Therapy and Its Effect on Plasma Pentraxin 3 In Patients with Chronic Kidney Disease on Renal Dialysis A Randomized Controlled Open Label Trial

Abstract

Patients on hemodialysis have a limited life expectancy due to multiple newlinecomorbidities and complications arising from cellular injury and inflammation. newlineMany studies have demonstrated that serum/plasma pentraxin 3 is a more sensitive newlinebiomarker for internal injury and inflammation compared to hsCRP. Vitamin E newlinepossesses strong anti-inflammatory and anticoagulant properties, and it also prevents newlinecell death caused by oxidative stress. Therefore, this study aims to explore the newlineclinical effectiveness of Vitamin E when used in conjunction with standard therapy, newlineand its relationship with plasma Pentraxin-3 levels in hemodialysis patients. Plasma newlinePentraxin-3 serves as a valuable biomarker for evaluating vascular injury and newlineinflammation. newlineOur study aimed to evaluate the impact of Vitamin E on plasma newlinepentraxin-3 levels in patients undergoing hemodialysis. The research was structured newlinewith three main objectives. First, we conducted a retrospective drug utilization and newlineevaluation study in the Department of Nephrology to assess current treatment newlinepractices and establish the standard therapy. Second, we evaluated the malnutrition newlinestatus of hemodialysis patients by measuring skinfold thickness and utilizing the newlineSGA-DMS tool to assess nutritional status and body fat percentage, ensuring the newlinetolerability of the fat-soluble investigational drug, Vitamin E, in these patients newline